Allergic asthma is a Th2-type dominated disease characterized by airway hyperreactivity (AHR) and eosinophilic inflammation. Although the asthma prevalence has increased strikingly, long-lasting effective therapies are missing. In this study, we tested the therapeutic potential of nasal DNA vaccination using a vector expressing murine Interleukin (IL)-10 or TGF-β1. Thereby, we combined the well-known Th1 favouring effects of unmethylated CpG motifs in the vector backbone and the anti-inflammatory activity of IL-10 or TGF-β1 respectively. Furthermore we examine mice with a deletion of TGF-β1 (TGF-β1+/--mice). At least we develop a new approach for geading mucus or inflammation in tissue sections by morphometric image analysis.